Skip to main content
ADIL
NASDAQ Life Sciences

10% Owner Buys $65K in Adial Pharmaceuticals Stock Post-Merger

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.595
Mkt Cap
$5.679M
52W Low
$1.31
52W High
$18.9
52W Position info
98% above low
Off High info
86% below high
Rel. Volume
Market data snapshot near publication time

ADIL sits 98% above its 52-week low of $1.31.

Summary

Coastlands Capital LP, a 10% owner of Adial Pharmaceuticals, purchased $65,000 worth of common stock, signaling continued confidence following the company's recent reverse merger and financing.


Key Events · Ownership and Investor Activity · ADIL

  • Significant Insider Purchase

    Coastlands Capital LP, a 10% owner, acquired 25,000 shares of common stock for $65,000 at $2.60 per share on June 29, 2026.

  • Post-Merger Confidence

    This purchase follows Adial Pharmaceuticals' recent reverse merger with Azora Therapeutics and a new financing deal, suggesting investor confidence in the company's strategic pivot.

  • Institutional Conviction

    The transaction represents a notable investment from a 10% owner, reinforcing positive sentiment after previous financial warnings and recent capital raises.


Analysis · ADIL · Life Sciences

This open market purchase by a significant institutional investor indicates conviction in Adial Pharmaceuticals after its recent reverse merger with Azora Therapeutics and a substantial financing deal. The purchase follows a period of financial uncertainty and a prior going concern warning, suggesting a positive outlook on the company's new strategic direction and improved capital position.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADIL was trading at $2.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $1.31 to $18.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADIL - Latest Insights

ADIL
Nov 12, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Nov 12, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Nov 09, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Oct 28, 2026, 5:56 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.08
Real-time Price: $4.86 info
Change: -$0.220 (-4%) info
Market Cap: $13.261M info
ADIL
Oct 28, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: -$0.0036 (-0.07%) info
Market Cap: $13.261M info